Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

TORONTO, March 24, 2026 — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement (“CTA”) with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

With the Clinical Trial Application (CTA) completed, RCH has now received final Research Ethics Board and operational approvals, including the final letter of authorization from Fraser Health. RCH will be the ninth site activated globally in the study and will be the fourth site to recruit patients in Canada.

Toronto General Hospital, part of University Health Network, St. Michael’s Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial.

The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States.

About Arch Biopartners

Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.

Arch’s development pipeline includes:

• LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI.
• Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI.
• CKD Platform: next-generation therapeutics targeting chronic kidney disease.

These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide1. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development.

For more details about the Company’s science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science

Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news.

The Company has 66,933,289 common shares outstanding.

For more information, please contact:

Aaron Benson Director of Communications Arch Biopartners, Inc. 647-428-7031

Send a message or subscribe for trial updates and company news at www.archbiopartners.com/contact-us